Beam Therapeutics Inc. (BEAM) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Beam Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Beam Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$98.7 M, a 2.29% decline year-over-year.
  • Beam Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$135 M, a 57.4% increase year-over-year.
  • Beam Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$133 M, a 54.2% increase from 2022.
  • Beam Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$289 M, a 22% increase from 2021.
  • Beam Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$371 M, a 90.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$135 M -$98.7 M -$2.21 M -2.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$133 M $143 M +$181 M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$314 M -$96.1 M +$13.5 M +12.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$327 M -$82.8 M -$10.8 M -15% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-08
Q1 2023 -$316 M -$96.5 M -$27.2 M -39.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$289 M -$38.3 M +$26.4 M +40.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$315 M -$110 M -$81.5 M -290% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$234 M -$72 M +$4.3 M +5.64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$238 M -$69.2 M +$132 M +65.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$371 M -$64.7 M +$30.8 M +32.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$401 M -$28.1 M +$6.33 M +18.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$408 M -$76.3 M -$42 M -123% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$366 M -$202 M -$171 M -562% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$195 M -$95.5 M -$67.6 M -243% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$127 M -$34.5 M -$15.4 M -81.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$112 M -$34.2 M -$16.4 M -91.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$95.2 M -$30.5 M -$16.8 M -124% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$78.3 M -$27.9 M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$19 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$17.9 M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$13.6 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.